Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
- Authors:
- Chi Pan
- Huijie Duan
- Yinan Wu
- Chunpeng Zhu
- Chenghao Yi
- Yin Duan
- Demin Lu
- Cheng Guo
- Deqi Wu
- Yanyan Wang
- Xianhua Fu
- Jing Xu
- Yiding Chen
- Meng Luo
- Wei Tian
- Tao Pan
- Wenhong Xu
- Suzhan Zhang
- Jianjin Huang
-
Affiliations: Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Cancer Institute (National Ministry of Education Key Laboratory of Cancer Prevention and Intervention), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of Breast Surgery, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Breast Surgery, The Zhejiang Provincial Hospital of Traditional Chinese Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of Gastrointestinal Thyroid and Breast Surgery, The Shulan (Hangzhou) Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China - Published online on: July 27, 2020 https://doi.org/10.3892/ijo.2020.5103
- Pages: 939-955
-
Copyright: © Pan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar | |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 coun-tries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
Burdett S, Stewart L and Pignon JP: Chemotherapy in non-small cell lung cancer: An update of an individual patient data-based meta-analysis. J Thorac Cardiovasc Surg. 129:1205–1206. 2005. View Article : Google Scholar : PubMed/NCBI | |
NSCLC Meta-Analyses Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 26:4617–4625. 2008. View Article : Google Scholar : PubMed/NCBI | |
Baselga J and Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs. 60(Suppl 1): S33–S42. 2000. View Article : Google Scholar | |
Singh M and Jadhav HR: Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today. 23:745–753. 2018. View Article : Google Scholar | |
Wu SG and Shih JY: Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI | |
Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI | |
Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, et al: Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 31:3342–3350. 2013. View Article : Google Scholar : PubMed/NCBI | |
Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, Ochi N, Tanimoto M and Kiura K: Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 319:417–423. 2013. View Article : Google Scholar : PubMed/NCBI | |
Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 33:1881–1888. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Luo F, Zhang Y, Ma Y, Hong S, Yang Y, Fang W, Huang Y, Zhang L and Zhao H: The ACTIVE study protocol: Apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Commun (Lond). 39:692019. View Article : Google Scholar | |
Kim D, Bach DH, Fan YH, Luu TT, Hong JY, Park HJ and Lee SK: AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. Cell Death Dis. 10:3612019. View Article : Google Scholar : PubMed/NCBI | |
Wang W, Wang H, Lu P, Yu Z, Xu C, Zhuang W and Song Z: Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: A multicenter retrospective study. J Transl Med. 17:522019. View Article : Google Scholar : PubMed/NCBI | |
Zhou H, Zeng C, Wang LY, Xie H, Zhou J, Diao P, Yao WX, Zhao X and Wei Y: Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: A meta-anal-ysis of 6,844 patients. Chin Med J (Engl). 126:3348–3355. 2013. | |
Fang H, Lin RY, Sun MX, Wang Q, Zhao YL, Yu JL, Tian Y and Wang XY: Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Asian Pac J Cancer Prev. 15:10967–10970. 2014. View Article : Google Scholar | |
Lee S, Joo J, Kwak M, Sohn K and Chon S: Role of chemo-therapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: A case report. Onco Targets Ther. 11:3943–3947. 2018. View Article : Google Scholar : | |
Ding T, Zhou F, Chen X, Zhang S, Liu Y, Sun H, Ren S, Li X, Zhao C, Wang H and Zhou C: Continuation of gefitinib plus chemo-therapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. J Thorac Dis. 9:2923–2934. 2017. View Article : Google Scholar : PubMed/NCBI | |
Anderson NG, Ahmad T, Chan K, Dobson R and Bundred NJ: ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer. 94:774–782. 2001. View Article : Google Scholar : PubMed/NCBI | |
Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S and Baselga J: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res. 9:1274–1283. 2003.PubMed/NCBI | |
Roberts JJ and Friedlos F: Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: Relationship to toxicity. Pharmacol Ther. 34:215–246. 1987. View Article : Google Scholar : PubMed/NCBI | |
Dijt FJ, Fichtinger-Schepman AM, Berends F and Reedijk J: Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48:6058–6062. 1988.PubMed/NCBI | |
Pera MF Jr, Rawlings CJ and Roberts JJ: The role of DNA repair in the recovery of human cells from cisplatin toxicity. Chem Biol Interact. 37:245–261. 1981. View Article : Google Scholar : PubMed/NCBI | |
Chu G and Berg P: DNA cross-linked by cisplatin: A new probe for the DNA repair defect in xeroderma pigmentosum. Mol Biol Med. 4:277–290. 1987.PubMed/NCBI | |
Shao CJ, Fu J, Shi HL, Mu YG and Chen ZP: Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol. 89:27–35. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ryu JS, Memon A and Lee SK: ERCC1 and personalized medicine in lung cancer. Ann Transl Med. 2:322014.PubMed/NCBI | |
Wang LR, He LJ, Wang Y, Li YY, Lou Y, Zhang GB, Li Y and Chen J: Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy. Cancer Chemother Pharmacol. 76:163–170. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang SC and Hung MC: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 15:6484–6489. 2009. View Article : Google Scholar : PubMed/NCBI | |
Rodemann HP, Dittmann K and Toulany M: Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol. 83:781–791. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, McIntush EW, Li LY, Hawke DH, Kobayashi R and Hung MC: Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol. 8:1359–1368. 2006. View Article : Google Scholar : PubMed/NCBI | |
Das AK, Chen BP, Story MD, Sato M, Minna JD, Chen DJ and Nirodi CS: Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 67:5267–5274. 2007. View Article : Google Scholar : PubMed/NCBI | |
Liccardi G, Hartley JA and Hochhauser D: EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 71:1103–1114. 2011. View Article : Google Scholar : PubMed/NCBI | |
Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lee GY, Kenny PA, Lee EH and Bissell MJ: Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods. 4:359–365. 2007. View Article : Google Scholar : PubMed/NCBI | |
Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L: Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29(Suppl 1): i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhang Q, Kanterewicz B, Shoemaker S, Hu Q, Liu S, Atwood K and Hershberger P: Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations. J Steroid Biochem Mol Biol. 136:264–270. 2013. View Article : Google Scholar | |
Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M and Nakagawa K: Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res. 69:6515–6521. 2009. View Article : Google Scholar : PubMed/NCBI | |
Li T, Ling YH, Goldman ID and Perez-Soler R: Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF and Frenkel EP: Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol. 4:161–166. 2009. View Article : Google Scholar : PubMed/NCBI | |
Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB and Johnston PG: Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther. 5:1154–1165. 2006. View Article : Google Scholar : PubMed/NCBI | |
Kim GW, Song JS, Choi CM, Rho JK, Kim SY, Jang SJ, Park YS, Chun SM, Kim WS, Lee JS, et al: Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. Lung Cancer. 88:139–146. 2015. View Article : Google Scholar : PubMed/NCBI | |
Karachaliou N, Rosell R, Molina MA and Viteri S: Predicting resistance by selection of signaling pathways. Transl Lung Cancer Res. 3:107–115. 2014. | |
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI | |
Denis MG, Vallée A and Théoleyre S: EGFR T790M resistance mutation in non small-cell lung carcinoma. Clin Chim Acta. 444:81–85. 2015. View Article : Google Scholar : PubMed/NCBI | |
Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 305:1163–1167. 2004. View Article : Google Scholar : PubMed/NCBI | |
Vitale MG, Riccardi F, Mocerino C, Barbato C, Monaco R, Galloro P, Gagliardi N and Cartenì G: Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: A case report. J Med Case Rep. 8:1022014. View Article : Google Scholar : PubMed/NCBI | |
Tsai CM, Chen JT, Stewart DJ, Chiu CH, Lai CL, Hsiao SY, Chen YM and Chang KT: Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: Why randomized trials failed? J Thorac Oncol. 6:559–568. 2011. View Article : Google Scholar : PubMed/NCBI | |
Laurila N and Koivunen JP: EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models. Med Oncol. 32:2052015. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Yang H, Yang X, Deng Q, Zhao M, Xu X and He J: Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases. Mol Clin Oncol. 2:449–453. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI | |
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005. View Article : Google Scholar : PubMed/NCBI | |
Rosetti M, Zoli W, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Granato AM, Amadori D and Silvestrini R: Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics. J Cell Physiol. 212:710–716. 2007. View Article : Google Scholar : PubMed/NCBI | |
Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, et al: Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses. J Clin Oncol. 35:4027–4034. 2017. View Article : Google Scholar : PubMed/NCBI | |
Melisi D, Troiani T, Damiano V, Tortora G and Ciardiello F: Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr Relat Cancer. 11:51–68. 2004. View Article : Google Scholar : PubMed/NCBI | |
Fujiwara K, Kiura K, Gemba K, Ogata Y, Hotta K, Kishino D, Tabata M, Ueoka H and Tanimoto M: Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients? Anticancer Res. 25:547–549. 2005.PubMed/NCBI | |
Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK and Perez-Soler R: Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydro-chloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res. 11:1572–1578. 2005. View Article : Google Scholar : PubMed/NCBI | |
Hilger RA, Scheulen ME and Strumberg D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 25:511–518. 2002. | |
Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W, Yuan Z, Wang LH and Cheng JQ: Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets. 8:2–6. 2008. View Article : Google Scholar : PubMed/NCBI | |
Sharrard RM and Maitland NJ: Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines. Cell Signal. 19:129–138. 2007. View Article : Google Scholar | |
Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M and Kudoh S: Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer. 92:1711–1719. 2005. View Article : Google Scholar : PubMed/NCBI | |
Albitar L, Carter MB, Davies S and Leslie KK: Consequences of the loss of p53, RB1, and PTEN: Relationship to gefitinib resistance in endometrial cancer. Gynecol Oncol. 106:94–104. 2007. View Article : Google Scholar : PubMed/NCBI | |
Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K, Kuwano M and Ono M: Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res. 70:8715–8725. 2010. View Article : Google Scholar : PubMed/NCBI | |
Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA and Hochhauser D: Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther. 5:209–218. 2006. View Article : Google Scholar : PubMed/NCBI | |
Friedmann B, Caplin M, Hartley JA and Hochhauser D: Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res. 10:6476–6486. 2004. View Article : Google Scholar : PubMed/NCBI | |
Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R and Rodemann HP: Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 280:31182–31189. 2005. View Article : Google Scholar : PubMed/NCBI | |
Dittmann K, Mayer C and Rodemann HP: Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol. 76:157–161. 2005. View Article : Google Scholar : PubMed/NCBI | |
Dittmann K, Mayer C, Czemmel S, Huber SM and Rodemann HP: New roles for nuclear EGFR in regulating the stability and translation of mRNAs associated with VEGF signaling. PLoS One. 12:e01890872017. View Article : Google Scholar : PubMed/NCBI | |
Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, et al: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 12:5064–5073. 2006. View Article : Google Scholar : PubMed/NCBI |